M
Marjeta Urh
Researcher at Promega
Publications - 52
Citations - 4220
Marjeta Urh is an academic researcher from Promega. The author has contributed to research in topics: Protein degradation & Fusion protein. The author has an hindex of 22, co-authored 47 publications receiving 3322 citations.
Papers
More filters
Journal ArticleDOI
HaloTag: A Novel Protein Labeling Technology for Cell Imaging and Protein Analysis
Georgyi V. Los,Lance P. Encell,Mark McDougall,Danette Hartzell,Natasha Karassina,Chad Zimprich,Monika G. Wood,Randy Learish,Rachel Friedman Ohana,Marjeta Urh,Daniel J. Simpson,Jacqui Méndez,Kris Zimmerman,Paul Otto,Gediminas Vidugiris,Ji Zhu,Aldis Darzins,Dieter Klaubert,Robert F. Bulleit,Keith V. Wood +19 more
TL;DR: The utility of this modular protein tagging system for cellular imaging and protein immobilization is demonstrated by analyzing multiple molecular processes associated with NF-kappaB-mediated cellular physiology, including imaging of subcellular protein translocation and capture of protein--protein and protein--DNA complexes.
Journal ArticleDOI
TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS
Rachel Deplus,Benjamin Delatte,Marie K. Schwinn,Matthieu Defrance,Jacqui Méndez,Nancy Murphy,Mark A. Dawson,Michael Volkmar,Pascale Putmans,Emilie Calonne,Alan H. Shih,Ross L. Levine,Olivier A. Bernard,Thomas Mercher,Eric Solary,Marjeta Urh,Danette L. Daniels,François Fuks +17 more
TL;DR: A step‐wise model, involving TET–OGT interactions, promotion of GlcNAcylation, and influence on H3K4me3 via SET1/COMPASS is unveiled, highlighting a novel means by which TETs may induce transcriptional activation.
Journal ArticleDOI
Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation
Omer Gilan,Omer Gilan,Inmaculada Rioja,Kathy Knezevic,Matthew J Bell,Miriam M. Yeung,Nicola Harker,Enid Y.N. Lam,Enid Y.N. Lam,Chun-wa Chung,Paul Bamborough,Massimo Petretich,Marjeta Urh,Stephen John Atkinson,Anna K. Bassil,Emma J. Roberts,Dane Vassiliadis,Dane Vassiliadis,Marian L. Burr,Marian L. Burr,Alex Preston,Christopher Roland Wellaway,Thilo Werner,James Gray,Anne Marie Michon,Thomas Gobbetti,Vinod Kumar,Peter Ernest Soden,Andrea C. Haynes,Johanna Vappiani,David F. Tough,Simon Taylor,Sarah-Jane Dawson,Sarah-Jane Dawson,Marcus Bantscheff,Matthew J Lindon,Gerard Drewes,Emmanuel Hubert Demont,Danette L. Daniels,Paola Grandi,Rab K. Prinjha,Mark A. Dawson,Mark A. Dawson +42 more
TL;DR: It is found that steady-state gene expression primarily requires BD1, whereas the rapid increase of gene expression induced by inflammatory stimuli requires both BD1 and BD2 of all BET proteins, which may guide future BET-targeted therapies.
Journal ArticleDOI
Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.
Sarah Picaud,Sarah Picaud,Oleg Fedorov,Oleg Fedorov,Angeliki Thanasopoulou,Katharina Leonards,Katherine Louise Jones,Julia Meier,Julia Meier,Heidi Olzscha,Octovia P. Monteiro,Octovia P. Monteiro,Sarah Martin,Sarah Martin,Martin Philpott,Martin Philpott,Anthony Tumber,Anthony Tumber,Panagis Filippakopoulos,Panagis Filippakopoulos,Clarence Yapp,Christopher Wells,Christopher Wells,Ka Hing Che,Andrew J. Bannister,Samuel Robson,Umesh Kumar,Nigel J. Parr,Kevin Lee,Dave Lugo,Philip D. Jeffrey,Simon Taylor,Matteo Vecellio,C. Bountra,Paul Brennan,Paul Brennan,Alison O'Mahony,Sharlene Velichko,Susanne Müller,Susanne Müller,Duncan Hay,Danette L. Daniels,Marjeta Urh,Nicholas B. La Thangue,Tony Kouzarides,Rab K. Prinjha,Jürg Schwaller,Stefan Knapp,Stefan Knapp +48 more
TL;DR: A novel, potent inhibitor targeting CBP/p300 bromodomains that impairs aberrant self-renewal of leukemic cells is reported that provides new opportunities for combinatorial treatment of leukemia and potentially other cancers.
Journal ArticleDOI
Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action.
Kristin M. Riching,Sarah D. Mahan,Cesear Corona,Mark McDougall,James D Vasta,Matthew B. Robers,Marjeta Urh,Danette L. Daniels +7 more
TL;DR: An innovative, modular live-cell platform utilizing endogenous tagging technologies is presented and applied to monitoring PROTAC-mediated degradation of the bromodomain and extra-terminal family members, showing comprehensive real-time degradation and recovery profiles for each target.